B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.